Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Tarning, Joel ^a,b   Kloprogge, Frank ^a,b   Piola, Patrice ^c   Dhorda, Mehul ^c,d   Muwanga, Sulaiman ^c   Turyakira, Eleanor ^c,e   Nuengchamnong, Nitra ^b   Nosten, François ^a,b,f   Day, Nicholas P J ^a,b   White, Nicholas J ^a,b   Guerin, Philippe J ^a,c   Lindegardh, Niklas ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MAHIDOL UNIVERSITY   (Thailand)

^c EPICENTRE   (France)

^d University of Maryland School of Medicine Center for Vaccine Development   (United States)

^e University of Science and Technology   (Uganda)

^f SHOKLO MALARIA RESEARCH UNIT   (Thailand)

Author keywords

Artemether; Dihydroartemisinin; Malaria; Non linear mixed effects modeling; Pharmacokinetics; Pregnancy

Indexed keywords

ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; BENFLUMETOL; DIHYDROARTEMISININ; DRUG METABOLITE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXPOSURE; DRUG TOLERABILITY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALARIA FALCIPARUM; POPULATION RESEARCH; PREGNANT WOMAN; SECOND TRIMESTER PREGNANCY; TANDEM MASS SPECTROMETRY; THIRD TRIMESTER PREGNANCY; UGANDA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; CHROMATOGRAPHY; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; MALARIA, FALCIPARUM; MASS SPECTROMETRY; MODELS, STATISTICAL; PLASMA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; UGANDA; YOUNG ADULT;

EID: 84865200031     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-293     Document Type: Article

References (54)

1. World Health Organization, World malaria report 2011
2. Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO, PLoS Med 2010 7 1000221 10.1371/journal.pmed.1000221 20126256
3. Malaria in pregnancy: pathogenesis and immunity. Rogerson SJ, Hviid L, Duffy PE, Leke RF, Taylor DW, Lancet Infect Dis 2007 7 105 117 10.1016/S1473-3099(07)70022-1 17251081
4. Artemisinin combination therapy for vivax malaria. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN, Lancet Infect Dis 2010 10 405 416 10.1016/S1473-3099(10)70079-7 20510281
5. World Health Organization, Guidelines for the treatment of malaria 2010
6. Influence of diethylcarbamazine and mefloquine on PGI2 synthesis by the rat thoracic aorta and myometrial tissues. El Tahir KE, Al-Kharji AM, Ageel AM, Gen Pharmacol 1991 22 837 846 10.1016/0306-3623(91)90216-S 1761188
7. Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers. Looareesuwan S, White NJ, Warrell DA, Forgo I, Dubach UG, Ranalder UB, Schwartz DE, Br J Clin Pharmacol 1987 24 37 42 10.1111/j.1365-2125. 1987.tb03133.x 3304385
8. Carrier-mediated partitioning of artemisinin into Plasmodium falciparum-infected erythrocytes. Vyas N, Avery BA, Avery MA, Wyandt CM, Antimicrob Agents Chemother 2002 46 105 109 10.1128/AAC.46.1.105-109.2002 11751119
9. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. McGready R, Stepniewska K, Lindegardh N, Ashley EA, La Y, Singhasivanon P, White NJ, Nosten F, Eur J Clin Pharmacol 2006 62 1021 1031 10.1007/s00228-006-0199-7 17053895
10. Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. McGready R, Stepniewska K, Ward SA, Cho T, Gilveray G, Looareesuwan S, White NJ, Nosten F, Eur J Clin Pharmacol 2006 62 367 371 10.1007/s00228-006-0118-y 16552504
11. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and non-pregnant women with uncomplicated malaria. Tarning J, Rijken MJ, McGready R, Phyo AP, Hanpithakpong W, Day NP, White NJ, Nosten F, Lindegardh N, Antimicrob Agents Chemother 2012 56 1997 2007 10.1128/AAC.05756-11 22252822
12. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Tarning J, McGready R, Lindegardh N, Ashley EA, Pimanpanarak M, Kamanikom B, Annerberg A, Day NP, Stepniewska K, Singhasivanon P, White NJ, Nosten F, Antimicrob Agents Chemother 2009 53 3837 3846 10.1128/AAC.00195-09 19564366
13. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. McGready R, Stepniewska K, Edstein MD, Cho T, Gilveray G, Looareesuwan S, White NJ, Nosten F, Eur J Clin Pharmacol 2003 59 545 552 10.1007/s00228-003-0652-9 12955371
14. Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. Nyunt MM, Adam I, Kayentao K, van Dijk J, Thuma P, Mauff K, Little F, Cassam Y, Guirou E, Traore B, Doumbo O, Sullivan D, Smith P, Barnes KI, Clin Pharmacol Ther 2010 87 226 234 10.1038/clpt.2009.177 19776738
15. Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. Karunajeewa HA, Salman S, Mueller I, Baiwog F, Gomorrai S, Law I, Page-Sharp M, Rogerson S, Siba P, Ilett KF, Davis TM, Antimicrob Agents Chemother 2009 53 4368 4376 10.1128/AAC.00335-09 19620325
16. Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. Green MD, van Eijk AM, van Ter Kuile FO, Ayisi JG, Parise ME, Kager PA, Nahlen BL, Steketee R, Nettey H, J Infect Dis 2007 196 1403 1408 10.1086/522632 17922406
17. Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. Na Bangchang K, Davis TM, Looareesuwan S, White NJ, Bunnag D, Karbwang J, Trans R Soc Trop Med Hyg 1994 88 321 323 10.1016/0035-9203(94)90101-5 7974678
18. Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. van Luin M, Van der Ende ME, Richter C, Visser M, Faraj D, Van der Ven A, Gelinck L, Kroon F, Wit FW, Van Schaik RH, Kuks PF, Burger DM, AIDS 2010 24 1223 1226 10.1097/QAD. 0b013e3283389129 20299957
19. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and non-pregnant women with uncomplicated falciparum malaria. Rijken MJ, McGready R, Phyo AP, Lindegardh N, Tarning J, Laochan N, Than HH, Mu O, Win AK, Singhasivanon P, et al. Antimicrob Agents Chemother 2011 55 5505 5506
20. Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy. Tarning J, Chotsiri P, Jullien V, Rijken MJ, Bergstrand M, Cammas M, McGready R, Singhasivanon P, Day NPJ, White NJ, et al. Antimicrob Agents Chemother 2012 In press
21. Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine- pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial. Sagara I, Rulisa S, Mbacham W, Adam I, Sissoko K, Maiga H, Traore OB, Dara N, Dicko YT, Dicko A, Djimdé A, Jansen FH, Doumbo OK, Malar J 2009 8 63 10.1186/1475-2875-8-63 19366448
22. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Abdulla S, Sagara I, Borrmann S, D'Alessandro U, Gonzalez R, Hamel M, Ogutu B, Martensson A, Lyimo J, Maiga H, Sasi P, Nahum A, Bassat Q, Juma E, Otieno L, Björkman A, Beck HP, Andriano K, Cousin M, Lefèvre G, Ubben D, Premji Z, Lancet 2008 372 1819 1827 10.1016/S0140-6736(08)61492-0 18926569
23. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Hatz C, Soto J, Nothdurft HD, Zoller T, Weitzel T, Loutan L, Bricaire F, Gay F, Burchard GD, Andriano K, Lefèvre G, De Palacios PI, Genton B, Am J Trop Med Hyg 2008 78 241 247 18256423
24. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy. McGready R, Tan SO, Ashley EA, Pimanpanarak M, Viladpai-Nguen J, Phaiphun L, Wustefeld K, Barends M, Laochan N, Keereecharoen L, Lindegardh N, Singhasivanon P, White NJ, Nosten F, PLoS Med 2008 5 253 10.1371/journal.pmed.0050253 19265453
25. Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Piola P, Nabasumba C, Turyakira E, Dhorda M, Lindegardh N, Nyehangane D, Snounou G, Ashley EA, McGready R, Nosten F, Guerin PJ, Lancet Infect Dis 2010 10 762 769 10.1016/S1473-3099(10)70202-4 20932805
26. How much fat is necessary to optimize lumefantrine oral bioavailability? Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Kham A, Brockman A, Singhasivanon P, White NJ, Nosten F, Trop Med Int Health 2007 12 195 200 10.1111/j.1365-3156.2006.01784.x 17300625
27. A liquid chromatographic-tandem mass spectrometric method for determination of artemether and its metabolite dihydroartemisinin in human plasma. Hanpithakpong H, Kamanikom B, Singhasivanon P, White NJ, Day NPJ, Lindegardh N, Bioanalysis 2009 1 37 46 10.4155/bio.09.6 21083186
28. Beal SL, Boeckman AJ, Sheiner LB, NONMEM user's Guides University of California at San Francisco: NONMEM Project Group 1992 22555854
29. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Lindbom L, Pihlgren P, Jonsson EN, Comput Methods Programs Biomed 2005 79 241 257 10.1016/j.cmpb.2005.04.005 16023764
30. Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Lindbom L, Ribbing J, Jonsson EN, Comput Methods Programs Biomed 2004 75 85 94 10.1016/j.cmpb.2003.11.003 15212851
31. NONMEMory: a run management tool for NONMEM. Wilkins JJ, Comput Methods Programs Biomed 2005 78 259 267 10.1016/j.cmpb.2005.02.003 15899310
32. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Jonsson EN, Karlsson MO, Comput Methods Programs Biomed 1999 58 51 64 10195646
33. Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Hietala SF, Martensson A, Ngasala B, Dahlstrom S, Lindegardh N, Annerberg A, Premji Z, Farnert A, Gil P, Bjorkman A, Ashton M, Antimicrob Agents Chemother 2010 54 4780 4788 10.1128/AAC.00252-10 20713675
34. Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. Salman S, Page-Sharp M, Griffin S, Kose K, Siba PM, Ilett KF, Mueller I, Davis TM, Antimicrob Agents Chemother 2011 55 5306 5313 10.1128/AAC.05136-11 21876056
35. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Gordi T, Xie R, Huong NV, Huong DX, Karlsson MO, Ashton M, Br J Clin Pharmacol 2005 59 189 198 10.1111/j.1365-2125.2004.02321.x 15676041
36. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. Ahn JE, Karlsson MO, Dunne A, Ludden TM, J Pharmacokinet Pharmacodyn 2008 35 401 421 10.1007/s10928-008-9094-4 18686017
37. Ways to fit a PK model with some data below the quantification limit. Beal SL, J Pharmacokinet Pharmacodyn 2001 28 481 504 10.1023/A:1012299115260 11768292
38. Handling data below the limit of quantification in mixed effect models. Bergstrand M, Karlsson MO, AAPS J 2009 11 371 380 10.1208/s12248-009-9112-5 19452283
39. Automated covariate model building within NONMEM. Jonsson EN, Karlsson MO, Pharm Res 1998 15 1463 1468 10.1023/A:1011970125687 9755901
40. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. Savic RM, Karlsson MO, AAPS J 2009 11 558 569 10.1208/s12248-009-9133-0 19649712
41. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO, AAPS J 2011 13 143 151 10.1208/s12248-011-9255-z 21302010
42. Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine. Ali S, Najmi MH, Tarning J, Lindegardh N, Malar J 2010 9 275 10.1186/1475-2875-9-275 20932349
43. Grapefruit juice increases the bioavailability of artemether. van Agtmael MA, Gupta V, van der Wosten TH, Rutten JP, van Boxtel CJ, Eur J Clin Pharmacol 1999 55 405 410 10.1007/s002280050648 10456492
44. Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Ilett KF, Ethell BT, Maggs JL, Davis TM, Batty KT, Burchell B, Binh TQ, le Thu TA, Hung NC, Pirmohamed M, Park BK, Edwards G, Drug Metab Dispos 2002 30 1005 1012 10.1124/dmd.30.9.1005 12167566
45. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Tracy TS, Venkataramanan R, Glover DD, Caritis SN, Am J Obstet Gynecol 2005 192 633 639 10.1016/j.ajog.2004.08.030 15696014
46. Variation of drug kinetics in pregnancy. Pavek P, Ceckova M, Staud F, Curr Drug Metab 2009 10 520 529 10.2174/138920009788897993 19689248
47. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Anderson GD, Expert Opin Drug Metab Toxicol 2006 2 947 960 10.1517/17425255.2.6.947 17125410
48. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Anderson GD, Clin Pharmacokinet 2005 44 989 1008 10.2165/00003088- 200544100-00001 16176115
49. The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. van Agtmael MA, Van Der Graaf CA, Dien TK, Koopmans RP, van Boxtel CJ, Eur J Drug Metab Pharmacokinet 1998 23 429 436 10.1007/BF03192305 9842988
50. The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. van Agtmael MA, Gupta V, van der Graaf CA, van Boxtel CJ, Clin Pharmacol Ther 1999 66 408 414 10.1053/cp.1999.v66.a101946 10546925
51. Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. van Agtmael MA, Cheng-Qi S, Qing JX, Mull R, van Boxtel CJ, Int J Antimicrob Agents 1999 12 151 158 10.1016/S0924-8579(99) 00063-1 10418761
52. A clinical and pharmacokinetic trial of six doses of artemether- lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Lefevre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon U, Gathmann I, Mull R, Bakshi R, Am J Trop Med Hyg 2001 64 247 256 11463111
53. Pharmacokinetic interaction trial between co-artemether and mefloquine. Lefevre G, Bindschedler M, Ezzet F, Schaeffer N, Meyer I, Thomsen MS, Eur J Pharm Sci 2000 10 141 151 10.1016/S0928-0987(00)00060-9 10727880
54. Pharmacokinetics of oral artemether in Thai patients with uncomplicated falciparum malaria. Karbwang J, Na-Bangchang K, Congpuong K, Thanavibul A, Wattanakoon Y, Molunto P, Fundam Clin Pharmacol 1998 12 242 244 10.1111/j.1472-8206.1998.tb00948.x 9565781